Pharmatest offers an in vitro model for studying chondrogenic differentiation and for identifying novel compounds with anabolic effects on chondrogenesis. The model is based on KS483 multipotent mouse mesenchymal progenitor cells that can be differentiated into chondrocytes, adipocytes and osteoblasts and are a well-characterized model for osteoblast differentiation and bone formation.

KS483 in vitro chondrogenic differentiation model can provide valuable data on the behavior of chondrocytes in relation to the development of OA, but it can also be applied in the study of other cartilage diseases and disorders.

In our assay, the chondrogenic differentiation is performed as pellet cultures where the cells are maintained in high-density pellets to mimic mesenchymal condensation during development.

The KS483 cells can be used as an in vitro 3D screening platform for drug testing of potential joint therapies and chondrogenic differentiation or for identifying compounds with inhibitory effects on chondrogenesis. The cells can be easily expanded and utilised for studies including large number of study groups and replicates.